The FDA on Monday approved a new drug for patients with advanced small cell lung cancer, permitting the treatment to be marketed based on less evidence than it traditionally requires in order to speed its path to market.

Madrid-based PharmaMar, which developed lurbinectedin (Zepzelca), licensed its US commercialization rights to Jazz Pharmaceuticals (NASDAQ: JAZZ) last December.

Now Jazz, which is based in Dublin, Ireland, but has significant US operations in Silicon Valley and Philadelphia, is preparing to make the drug a treatment option for adults whose small cell lung cancer (SCLC) has spread to other parts of the body and… Read more »